Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Immunogen Research and Development Expense (Quarterly): 47.57M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 47.57M |
| June 30, 2023 | 50.08M |
| March 31, 2023 | 51.62M |
| December 31, 2022 | 58.48M |
| September 30, 2022 | 59.18M |
| June 30, 2022 | 51.42M |
| March 31, 2022 | 44.28M |
| December 31, 2021 | 48.97M |
| September 30, 2021 | 33.15M |
| June 30, 2021 | 34.59M |
| March 31, 2021 | 34.41M |
| December 31, 2020 | 39.58M |
| September 30, 2020 | 24.68M |
| June 30, 2020 | 22.92M |
| March 31, 2020 | 27.41M |
| December 31, 2019 | 26.06M |
| September 30, 2019 | 21.02M |
| June 30, 2019 | 28.56M |
| March 31, 2019 | 38.89M |
| December 31, 2018 | 43.68M |
| September 30, 2018 | 47.24M |
| June 30, 2018 | 38.70M |
| March 31, 2018 | 44.83M |
| December 31, 2017 | 39.84M |
| September 30, 2017 | 31.69M |
| Date | Value |
|---|---|
| June 30, 2017 | 35.32M |
| March 31, 2017 | 32.89M |
| September 30, 2016 | 32.91M |
| June 30, 2016 | 38.65M |
| March 31, 2016 | 36.09M |
| December 31, 2015 | 38.20M |
| September 30, 2015 | 35.13M |
| June 30, 2015 | 30.44M |
| March 31, 2015 | 25.67M |
| December 31, 2014 | 27.65M |
| September 30, 2014 | 28.02M |
| June 30, 2014 | 25.79M |
| March 31, 2014 | 38.28M |
| December 31, 2013 | 20.86M |
| September 30, 2013 | 22.03M |
| June 30, 2013 | 20.40M |
| March 31, 2013 | 21.32M |
| December 31, 2012 | 21.66M |
| September 30, 2012 | 23.70M |
| June 30, 2012 | 19.54M |
| March 31, 2012 | 16.93M |
| December 31, 2011 | 15.56M |
| September 30, 2011 | 17.16M |
| June 30, 2011 | 18.26M |
| March 31, 2011 | 15.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
21.02M
Minimum
Sep 2019
59.18M
Maximum
Sep 2022
39.11M
Average
37.08M
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie Inc | 1.939B |
| Pfizer Inc | 2.493B |
| Johnson & Johnson | 3.542B |
| Merck & Co Inc | 3.992B |
| Cerevel Therapeutics Holdings Inc | 97.13M |